Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD) — Haian Fu (EMORY UNIVERSITY)
SUMMARY Lung cancer is the leading cancer killer in the United States. Our team proposes to develop novel personalized therapeutic strategies by exploiting vulnerabilities and opportunities created by
| Project title | Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD) |
|---|---|
| Project number | 5P01CA257906-02 |
| PI name | Haian Fu |
| Institution | EMORY UNIVERSITY |
| Funding mechanism | P01 |
| Agency | NCI |
| Award amount | $2.16M |
| Fiscal year | 2023 |
| Project start | 2022-06-01T00:00:00 |
| Project end | 2027-05-31T00:00:00 |
| Abstract | SUMMARY Lung cancer is the leading cancer killer in the United States. Our team proposes to develop novel personalized therapeutic strategies by exploiting vulnerabilities and opportunities created by |
| Key terms | <ATP-protein phosphotransferase><Address><B-raf-1><BRAF><BRAF gene><Bio-Informatics><Bioinformatics> |
$799/mo
Try GrantRadar →